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Abstract
Objective: Given that volumes of patients and interventions are important criteria to qualify as a reference centre (RC) 
for the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the present study aimed to evaluate 
the data that were reported in the original application against subsequent assessments of activity and review the 
criteria that may define RCs using two main thematic groups (MTGs): Pituitary and Thyroid, as examples.
Methods: Review of content in application forms and continuous monitoring data and of a survey distributed to RCs. 
A list of ‘key procedures’ for the assessment of performance of RCs was composed with the help of the Pituitary and 
Thyroid MTG chairs.
Results: In the original application, the number of undefined procedures ranged from 20 to 5500/year (Pituitary) and 
from 10 to 2700/year (phyroid) between applicants. In the survey, the number of key procedures per centre ranged 
from 18 to 150/year (Pituitary) and from 20 to 1376/year (Thyroid). The median numbers of new patients reported 
in the continuous monitoring program were comparable with the application and survey; however, some centres 
reported large variations.
Conclusions: Monitoring of clinical activity in an ERN requires clear definitions that are optimally aligned with clinical 
practice, diagnosis registration, and hospital IT systems. This is a particular challenge in the rare disease field where 
the centre may also provide expert input in collaboration with local hospitals. Application of uniform definitions, in 
addition to condition-specific clinical benchmarks, which can include patient-reported- as well as clinician-reported 
outcome measures, is urgently needed to allow benchmarking of care across Endo-ERN.
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Introduction
In March 2017, 24 European Reference Networks (ERNs) 
were officially installed under the directive 2011/24/EU on 
patient’s rights in cross-border health care. The mission of 
ERNs is to reduce health care inequalities for all patients 
with rare and/or complex conditions across the European 
Union (EU). This is to be achieved through cross-border 
expert consultation and guideline conformity, enabling 
the highest standard of care. The European Reference 
Network on Rare Endocrine Conditions (Endo-ERN), at 
present, is the largest ERN and comprises 71 reference 
centres (RCs) representing 19 countries. Endo-ERN 
has divided the European landscape for rare endocrine 
conditions in eight main thematic disease areas, the Main 
Thematic Groups (MTGs), and covers both paediatric and 
adult expertise. The MTGs, which are organ and physiology 
based, are: Adrenal, Disorders of calcium & phosphate 
homeostasis, Genetic disorders of glucose & insulin 
homeostasis, Genetic endocrine tumour syndromes, 
Growth & genetic obesity syndromes, Pituitary, Sex 
development & maturation, and Thyroid. Each MTG 
includes subthemes of several specific conditions based on 
hormonal overproduction, -insufficiency, -resistance and/
or tumour growth. Endo-ERN’s mission is to reduce and 
ultimately abolish inequalities in care for patients with 
rare endocrine disorders in Europe, through facilitating 
knowledge sharing and related health care and research. 
The mission of Endo-ERN is defined in five work packages 
(WPs): (1.) Education and Training, (2.) E-health and ICT, 
(3.) Research and Science, (4.) Quality of Care & Patient 
View, and (5.) Diagnostics & Laboratory analysis.
The 2016 application to the first call for ERN 
membership was eligible only for centres that had 
obtained national endorsement for specific, rare disease 
expertise. This advice to the member states was to base 
the endorsement on the EUCERD criteria (1), that, among 
others, include participation in a regional or national 
assessment program, patient-centred organization of 
care, and on highly specific interventions covered by 
the health care provider. These requirements were very 
differently handled depending on national health care 
system organization and legal context. A generic EU 
application form for all ERNs had to be completed, that 
included numbers of new patients, patients under chronic 
care, and procedures (e.g. operations, radiotherapy, or 
other complex interventions, but in this application, it 
was not specified in detail) performed over the last 3 years. 
Centres were evaluated according to Endo-ERN-specific 
network criteria, which were proposed after discussion by 
the (future) steering committee, and included an expert 
based minimal volume of new and chronic patients and 
surgical volumes. If they were available, these were based 
on international guidelines. At this stage, this process 
was a novelty both for the EU and potential RCs. No 
endocrine disease network was in place and there were 
tight deadlines. Therefore, not a condition specific but a 
generic application form was provided by the EU. No clear 
instructions were provided on how to define a new or 
chronic patient (i.e. first-time diagnosis or first-time visitor 
in that specific hospital for example), and no guidance 
was provided on how to retrieve these numbers from 
the hospital systems. Consequently, RCs were allowed to 
report according to their discretion (use of own strategy), 
using their local systems and practices to retrieve patient 
and interventions volumes. As a consequence, definitions 
of intervention were interpreted by centres very variably. 
Interpretations ranged from surgical procedures only to 
a diverse spectrum of procedures, including all dynamic 
hormone tests.
The aim of the present study was to evaluate how 
self-reported volume data in the original applications 
were obtained. Next, using a survey, we tried to obtain 
insight into which data were considered retrievable and 
which data set is best to use for future centre evaluations. 
In particular, what is the best definition of a new patient, 
a patient under chronic care, and what interventions 
should be registered to define a reference centre. Because 
of the large size of the network and the heterogeneity of 
subgroups of conditions, both between and within MTGs, 
we decided to focus on two example MTGs: Pituitary (43 
RCs) and Thyroid (35 RCs).
Methods
Analysis of original application forms (submitted 
in 2016, data from 2013, 2014, and 2015)
We retrieved and analysed the data from the original 
network applications of the individual RCs participating 
in the two specific MTGs of Endo-ERN. The following 
data were extracted: total number of new patients, total 
number of patients under chronic care, and total number 
of procedures per year of the years 2013–2015, and per 
sub-theme. Subsequently, we calculated the means for 
the reported 3 years. Additionally, a distinction was 
made between RCs covering adult expertise, paediatric 
expertise, or both. The application form can be found in 
the supplementary files.
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Survey on RCs interpretation on 
definitions (2018–2019)
We aimed to obtain more clarity on the strategies used by 
the participating RCs to define new patients and procedures 
in the original application. Furthermore, we wanted to 
assess future possibilities to extract more reliable, uniform 
data and to identify barriers in extracting patient numbers 
and interventions. A survey was developed under the 
guidance of the adult chairs of both MTGs (NRB and RPP). 
The survey captured the number of new patients, the 
number of patients under chronic care, and the number 
of procedures performed following uniform definitions. 
The definition of a new patient was ‘any treatment 
naive patient, and/or any new patient for the healthcare 
provider’. Definition of a patient under chronic care was ‘a 
patient under chronic treatment at the RC, not including 
remote consultations or referrals for specific testing only’. 
A list of the key procedures was composed which were 
considered to be relevant for the specific conditions covered 
by MTGs Pituitary and Thyroid. Centres were also asked 
to provide numbers on key procedures and availability of 
other specialized care. For MTG Pituitary, the following 
key procedures were defined: (1.) transsphenoidal surgery, 
(2.) conventional radiotherapy, (3.) radiosurgery, and 
(4.) genetic testing for hypopituitarism. Furthermore, 
the availability of medical treatment, bilateral inferior 
petrosal sinus sampling, dynamic hormone testing, and 
multidisciplinary care pathways were surveyed. For MTG 
Thyroid, the key procedures were (1.) thyroid surgery, 
(2.) radioiodine therapy, and (3.) molecular analysis for 
radioiodine-sensitive and non-metastatic medullary 
thyroid carcinoma. Availability was captured for novel 
drugs and personalised therapy for rare genetic thyroid 
disease and emerging genetic studies and new-born 
screening in congenital hypo- and hyperthyroidism. The 
survey was sent via e-mail to all RCs participating in MTGs 
Pituitary, Thyroid, or both. In case of no response, centres 
that did not respond prior to the given deadline were 
contacted up to a maximum of three times. The full survey 
can be found in the supplementary files. The survey was 
distributed to 51 RCs. Twenty-seven RCs participated in 
both of the MTGs Pituitary and Thyroid.
Comparison with data obtained for the continuous 
monitoring program of ERNs (data from 2017 
to 2018)
Recently, the EU introduced a continuous monitoring 
program for all ERNs. This program includes mandatory 
periodic reporting on 18 general key performance 
indicators. These are not condition- or ERN-specific. 
Among these performance indicators are the number of 
new patients seen per year (to start with 2017 and 2018). 
Currently, this is a feature to compare numbers between 
ERNs. In the future, this will likely be used to monitor 
the performance of the specific ERN as well as individual 
RCs. These numbers were extracted from the monitoring 
forms provided to the EC. As in the original network 
applications, no clear definitions were provided.
Statistical analysis
Descriptive statistics were used to present data. 
Population data from the EU countries were extracted 
from the Eurostat website (https://ec.europa.eu/eurostat/
databrowser/view/tps00001/default/table?lang=en, 
access date 05–02-2020). Statistical analysis was 
performed using IBM SPSS statistics 25.0 (IBM Corp. 
Released 2017).
Results
Description of both MTGs
Pituitary is the largest MTG of Endo-ERN and includes 43 
RCs from 15 countries, with the highest representation in 
Italy and the United Kingdom (8 RCs) (Fig. 1A). Thyroid 
includes 35 RCs from 14 countries, with Germany being 
the best represented with 7 RCs (Fig. 1B).
Evaluation of application
MTG Pituitary
The number of new patients per RC per year ranged from 
6 to 276 (median: 93, IQR: 69–135) and from 60 to 2494 
per year for patients under chronic care (median: 793, 
IQR: 452–1213). The number of procedures during the 
3-year period ranged from 20 to 5500 (median: 572, IQR 
179–1085).
MTG Thyroid
The number of new patients per RC per year ranged from 
3 to 699 (median: 61, IQR: 30–98) and of patients under 
chronic care from 4 to 9999 (median: 315, IQR: 136–487). 
The number of procedures per RC per year ranged from 10 
to 2700 (median: 277, IQR: 73–686).
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Evaluation of surveys
Definitions of patients (new patient and patient under 
chronic care)
Twenty-three unique centres answered the question in 
our survey on how they defined a new patient in the 
application forms. One centre (4%) only defined treatment 
naive patients as new patients. Seventeen centres (74%) 
defined a new patient only as any patient not previously 
seen by the RC. Four centres (17%) defined any treatment 
naive patient as a new patient. One RC (4%) defined a 
new patient as any patient that was administratively 
considered a new patient because the interval between the 
last and present consultation exceeded a period of 1 year, 
in addition to any patient not previously seen by the RC.
Twenty-four unique centres answered the question 
of how they defined a patient under chronic care in the 
application forms. Any chronic patient being a patient under 
long-term treatment at the reference centre was reported 
unanimously as a patient under chronic care. In addition, 
three (13%) centres included patients being referred to 
their centre for a single consultation only, three (13%) for 
diagnostic tests only, six (25%) for a specific procedure, and 
four (17%) as patients with previous treatment in the RC, 
but referred back to the affiliated centres as chronic patients.
To the question in which way the numbers were 
obtained, a variety of answers were received. Some 
centres retrieved numbers from a national database on 
rare endocrine conditions, some via diagnosis based 
institutional IT-systems, while others used systems 
intended for care declarations, and finally personal 
disease-specific databases were used.
MTG Pituitary
Patients: Twenty-eight of 43 RCs (65%) provided 
information both on the number of new patients and 
the number of patients under chronic care. The median 
number of new patients was: 110, 105, and 101 in 
2013, 2014, and 2015, respectively (range 1–318/year). 
Regarding patients under chronic care, the median 
number of patients was 845, 876, and 837 for 2013, 2014, 
and 2015, respectively (range 12–2535/year) (Table 1).
Procedures: The total number of key procedures by 
centres ranged from 18 to 150/year, with a median of 66 
procedures/year.
Subtheme pituitary adenoma: All RCs provided 
medical treatment and multidisciplinary care, 93% of 
the RCs provide transsphenoidal surgery, and 89% also 
conventional radiotherapy, while radiosurgery is available 
in only 36% of centres. Inferior petrosal sinus sampling is 
offered by 85% of the RCs (Fig. 2). Transsphenoidal surgery 
is the most frequently performed procedure in patients 
with pituitary adenoma, with a median number of surgeries 
performed per centre of 48, 46, and 50 in 2013, 2014, 
and 2015, respectively (range 9–120/year). Conventional 
radiotherapy was performed in a median of five, four, and 
four patients in 2013, 2014, and 2015, respectively (range 
0–15/year). Radiosurgery was performed in a median 
number of three (range 0–24) patients per year in 2013, 
2014, and 2015, respectively (Table 1).
Subthemes congenital and acquired hypopituitarism: 
All RCs provided dynamic hormone testing, medical 
treatment, and multidisciplinary care. Genetic testing was 
available in 85% of the RCs (Fig. 2). The median number 
of performed genetic tests for congenital hypopituitarism 
were 20, 20, and 18 per year (range 1–86/year) and 10, 9, 
and 8 (range 0–50/year) for acquired hypopituitarism in 
2013, 2014, and 2015, respectively (Table 1).
MTG Thyroid
Patients: Twenty-four of 35 RCs (69%) completed the 
survey. The median number of new patients was 50, 56, 
Figure 1
Number of RCs participating in (A) MTG 
Pituitary and (B) MTG Thyroid per country.
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and 59 for 2013, 2014, and 2015, respectively (range 
11–682/year). Regarding patients under chronic care, the 
median number of patients was 237, 363, and 399 for 
2013, 2014, and 2015, respectively (range 0–11.021/year) 
(Table 1).
Procedures: The total number of key procedures by 
centres ranged from 20–1376/year, with a median of 150 
procedures/year.
Subtheme rare genetic thyroid disease: Treatment 
with novel drugs for rare genetic thyroid disease and 
personalised therapy was available in 46% and 59% of the 
RCs, respectively (Fig. 2).
Subtheme congenital hypo- and hyperthyroidism: 
Neonatal screening was provided by 77% of the RCs, and 
55% of the RCs participated in emerging genetic studies 
with regards to treatment (Fig. 2).
Subtheme thyroid carcinoma: All RCs provided thyroid 
surgery. Therapy with radioactive iodine was available in 
91% of the RCs for those patients with radioactive iodine-
sensitive thyroid carcinoma. Molecular analysis of the 
tumour was available in 87% of the RCs (Table 1). Thyroid 
surgery was the most frequently performed procedure (a 
median number of procedures: n = 64, 73, and 83 (range 
0–497/year), in 2013, 2014, and 2015, respectively). 
Radioiodine therapy was provided in 52, 52, and 57 
patients (median for 2013, 2014, and 2015, respectively, 
range 0–910/year). Molecular analysis was performed in a 
median number of 10, 13, and 12 patients in 2013, 2014, 
and 2015, respectively (range 0–380/year) (Table 1).
Continuous monitoring program for ERNs 
(reported data for 2017 and 2018)
MTG Pituitary
The median number of new patients was 80 and 88 
(range 3–919/year) for 2017 and 2018, respectively. The 
median number of new patients per year was somewhat 
lower than those reported for 2013–2015. However, the 
maximum number of new patients reported per year 
increased threefold in only 3 years’ time. In four centres, 
the reported number of new patients per year had at least 
doubled since the first application, whereas two centres 
now reported more than 50 new patients for the first time.
Table 1 Number of patients seen, specific procedures performed by the RCs participating in MTG Pituitary and MTG Thyroid in 
the survey for 2013, 2014, and 2015, and number of new patients in 2017 and 2018 reported for the ERN continuous monitoring 
program. Data are presented as median (range).
2013 2014 2015 2017 2018
MTG Pituitary 
 New patients 110 (1–294) 105 (1–318) 101 (1–298) 80 (1–944) 88 (4–893)
 Chronic patients 845 (12–2,500) 876 (13–2,520) 837 (14–2,535) - -
 Transsphenoidal surgery 48 (9–100) 46 (9–110) 50 (9–120) - -
 Conventional radiotherapy 5 (0–10) 4 (0–12) 4 (0–15) - -
 Radiosurgery 3 (0–15) 3 (0–20) 3 (1–24) - -
 Genetic analysis 20 (1–50) 20 (1–86) 18 (1–50) - -
MTG Thyroid 
 New patients 50 (14–650) 56 (11–641) 59 (15–682) 95 (0–792) 89 (1–864)
 Chronic patients 327 (0–11,021) 363 (0–10,926) 399 (0–10,940) - -
 Surgery 64 (0–391) 73 (0–472) 83 (1–497) - -
 Radioiodine therapy 52 (0–910) 52 (0–861) 57 (0–874) - -
 Molecular analysis 10 (0–300) 13 (0–350) 12 (1–380) - -
Figure 2
Availability of specialized procedures in the reference centres 
of (A) MTG Pituitary and (B) MTG Thyroid. MDT: 
Multidisciplinary Consultation and treatment; Med: Medical 
treatment; TSS: Transsphenoidal Surgery; RTx: conventional 
radiotherapy; GK: radiosurgery; DynTest: Dynamic Testing; 
GenTest: Genetic Testing; PersTh: Personalised Therapy; 
NovDrugs: Novel Drugs; NeonScr: Neonatal Screening; GenScr: 
Genetic Screening; ThSurg: Thyroid Surgery; I-131: Radioactive 
Iodine I-131 Therapy; MolAn; Molecular Analysis.
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MTG Thyroid
The median number of new patients was 95 and 89 (range 
0–864/year) for 2017 and 2018, respectively. The median 
and maximum number of new patients per year were 
somewhat higher than those reported for 2013–2015. 
However, the minimum number of new patients per 
year decreased to zero. Twelve centres reported at least a 
doubling in number of new patients per year since the first 
application, whereas one centre surpassed the 50-new-
patients-per-year mark.
Discussion
This paper outlines the progress within Endo-ERN 
to establish valuable and reliable measures on the 
performance of this rare disease network (Fig. 3). This 
report provides valuable insights into activities and its 
reporting in the landscape of rare endocrine conditions at 
the launch of Endo-ERN, in particular for the two MTGs 
described: Pituitary and Thyroid. Endo-ERN can provide 
unique, valuable information on clinical activities in the 
care of rare endocrine conditions throughout Europe. 
However, there is an urgent need to clearly define key 
performance indicators, such as new and chronic patients 
and to have an upfront discussion on which procedures 
and interventions best indicate an expert centre, to 
evaluate the performance of, and characterize RCs. In 
the original, generic application, no definitions on the 
requested numbers were provided. The survey indicated 
that a proportion of the variation in performed procedures 
was among other reasons due to a lack of clear definitions, 
and consequently, this resulted in the use of different 
definitions by the RCs. For example, one centre very strictly 
defined a ‘new patient’ only as a patient diagnosed in that 
centre and did not report patients or disease-specific key 
procedures from its collaborative centre in the same city. 
This centre reported one new pituitary patient per year. 
A different centre defines ‘new patients’ as a patient not 
previously seen by the hospital and reports total numbers 
from all their collaborative centres and reports over 200 
new pituitary patients per year. From 2019 onwards, the 
ERN continuous monitoring program has now adjusted 
the definition for the key performance indicator ‘new 
patients’ to: ‘Total number of new patients referred to the 
Health Care Providers participating in the ERN with the 
diagnosis of a disease/condition that fall within the scope 
of the ERN’. Moreover, we found that when key procedures 
are established and measured per MTG or MTG-subgroup, 
reliable and comparable numbers concerning specialized 
care can be obtained from the RCs. Unfortunately, the 
implementation of the continuous monitoring program 
for already existing reference centres and the preparation 
Figure 3
Visual representation of the progress within Endo-ERN and European Commission to establish valuable and reliable measures on 
the performance of this rare disease network. The red arrows and connected boxes indicate measurements included in this 
paper. The application form and CMQS included more measurements we did not report on. ERN: European Reference Network; 
EC: European Commission; MTG: Main Thematic Group; CMQS: Continuous Monitoring and Quality Improvement System; CRO: 
Clinician-Reported Outcome; PRO: Patient-Reported Outcome.
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of the second call at least partly overlapped with our study 
period. Consequently, the documents used in this call do 
not yet incorporate our findings. Therefore, the second 
application round was started using the same process as 
in the first application round. Nevertheless, the reviewers 
are aware of the identified heterogeneity in numbers and, 
although not yet incorporated in the formal criteria, the 
reviewers will request clarification in case of unclearly 
defined numbers.
A mission of Endo-ERN is to capture all rare endocrine 
conditions throughout the life span in all EU countries. 
However, this is also an important limitation. A large 
variety of diseases also means a large variety in needs, 
complexity, and in mechanisms of care provision. These 
not only depend on disease group, but also on country-
specific organisation of care. Within a European network, 
heterogeneity in care organisation will always occur. This 
prohibits full alignment in care provision between all 
Endo-ERN centres.
In this process, we have learned that there are 
local and national variations with respect to diagnosis 
registration and challenges with extracting patient 
numbers from hospital files. These considerations have to 
be taken into account when developing new measures. 
As a first step, the centres within Endo-ERN need to be 
aligned on the definition of these measures. Through 
the European Registries for Rare Endocrine Conditions 
(EuRRECa) project (https://eurreca.net/, access date 
05–02-2020) and in collaboration with the European 
Society of Endocrinology and the European Society for 
Paediatric Endocrinology, Endo-ERN has developed an 
e-reporting platform which can now be used for collecting 
monthly reports on clinical encounters (https://eurreca.
net/e-rec/, access date 05–02-2020). e-REC provides 
a unique identifier for each new case that has a rare 
condition covered within Endo-ERN and will provide 
clarity about new and chronic patients, even in shared 
care situations. The periodical electronic reporting of 
cases using e-REC is based on the number of new patients 
seen per MTG per month and currently is implemented 
in the RCs. Preliminary data generated from e-REC shows 
clear variation in reported cases per MTG and per RC (2). 
Once e-REC is fully implemented, not only will it become 
an invaluable data for epidemiological surveillance, but 
this simple activity may also facilitate endorsements of 
centres as well as targeted condition-specific activities 
aimed at quality improvement including peer-review 
programs, such as that introduced in the field of diabetes 
and endocrinology (https://www.endocrinology.org/
clinical-practice/interdepartmental-peer-review/ and 
https://www.sweet-project.org/peer-review-program.php, 
access date 05–02-2020). At present, reference centres 
are already encouraged to provide numbers for the 
continuous monitoring program via e-REC. Moreover, 
the core endocrine registry in EuRRECa complements 
the e-REC platform by having the functionality that 
allows collection of generic and condition-specific core 
outcomes that can be directly reported by patients and 
health care professionals and used as clinical benchmarks 
in the long-term.
We observed a large range of reported patient numbers 
by the RCs, that first of all and most likely is influenced 
by differences in the population size these RCs provide 
care for. These catchment areas differ tremendously both 
between RCs and countries. For example, the collaborating 
centres in the Paris metropolitan area have a coverage of 
over 12 million inhabitants, which is about nine times 
the population of Estonia. Moreover, differences in 
the organisation of the care (for rare diseases) between 
countries and regions clearly also affect the numbers. 
For instance, French RCs report on a higher number of 
patients and procedures as compared with other countries 
that participate in MTGs Pituitary and Thyroid. A likely 
explanation for these observations is the specific care 
structure for rare diseases in France. In 2006, a network 
for rare endocrine diseases, named Firendo, was installed 
(http://www.firendo.fr/de/home-firendo-the-french-rare-
endocrine-disease-network/, access date 05–02-2020). This 
national ‘3 layer’ network consists of one coordinating 
reference centre, three constitutive centres, and 29 
competence centres, with a structured and pre-defined 
way in which the referral of patients is organised. The 
structure of Endo-ERN was partly based on this model. The 
presence of this national and effective referral network in 
France can explain, at least in part, the high number of 
patients seen and procedures performed by the specialized 
(pituitary) care providers. It is expected that in countries 
with a similar care structure the reported numbers will be 
higher because of these intrinsic features of centralisation 
of care. On the contrary, The Netherlands, for example, 
has established regional referral systems, but a nationwide 
system has not yet been developed.
When comparing the number of new patients 
reported for the 2013–2015 period to the numbers 
obtained for the continuous monitoring program for 
ERNs (2017–2018), the median numbers of reported 
new patients are comparable. However, when looking 
at the level of individual RCs, significant increases and 
decreases are reported by several RCs. These could be the 
consequence of a new referral system or use of adjusted 
Downloaded from Bioscientifica.com at 09/08/2020 09:35:42AM
via University of Glasgow
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
183:2 148Clinical Study F de Vries, M Bruin and 
others
Evaluation of performance in 
Endo-ERN
https://eje.bioscientifica.com
definitions, but also merely reflect real changes in patient 
numbers and/or procedures. However, without knowledge 
of the care provided to these patients, it is hard to draw 
any conclusions on centre performance. If an RC provides 
complex care only within a decentralised system, this does 
not necessarily have to result in or reflect on lower quality 
of care. On the contrary, centralizing all the care for a 
specific condition will result in higher numbers of new 
patients, but may not necessarily result in the provision 
of more complex care by the RC. While a certain surgical 
volume is important for improved outcomes (3, 4), a 
direct relationship between the volume of patients per 
hospital and patient outcomes is not clear in all fields (5). 
Therefore, we advocate the use of specific key procedures in 
measuring provided care. To acquire clinically meaningful 
data, the procedures should be prioritized per specific field 
of expertise, of which the availability and frequency are 
most important for the evaluation of the performance 
of an RC. We acknowledge that a higher number of 
performed procedures will not reflect the quality of this 
procedure. Therefore, expert discussion is necessary to 
develop core outcome sets that can be measured. These 
outcome sets can include clinician-reported outcome 
measures as well as patient-reported outcome measures, 
such as health-related quality of life.
In conclusion, we describe the current pathway towards 
reliably quantifying performance measures within Endo-
ERN. The first steps towards this goal have been taken. 
However, we advocate that definitions should be provided 
with the questionnaires when evaluating numbers of new 
and chronic patients. Furthermore, objective benchmarks 
of clinical practice should be developed for the subthemes 
of each MTG or MTG-subgroup separately. The number of 
performed ‘core procedures’ should be recorded as well as 
the availability of highly specialized care. This will result 
in numbers that are suitable for comparison, thereby 
increasing the ability to evaluate the performance and 
coverage of Endo-ERN over time.
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